car t cell

Since the first approvals of chimeric antigen receptor (CAR)-T cell immunotherapies in 2017, they have showcased their potential as long-lasting treatments for cancer. This impact was felt not just in the CAR-T cell therapy space but also other forms of cancer cell therapy. “The T-cell space has been the primary focus of interest in the…